Docetaxel use associated with significant reduction in prostate cancer death in very poor prognostic group

Males with high-grade prostate most cancers and low prostate-specific antigen (PSA) ranges have a poor prognosis. The query stays as as to whether the chemotherapy drug docetaxel, which will increase survival in metastatic prostate most cancers, can enhance the remedy price in these sufferers.

In a brand new research by investigators from Brigham and Girls’s Hospital, a meta-analysis of 5 potential randomized clinical trials (RCTs) discovered that including docetaxel to standard-of-care (SOC) therapy was related to a 70% discount in demise from prostate cancer-specific mortality (PCSM). The research was printed right now in JAMA Network Open.

Investigators carried out a meta-analysis of the RCTs evaluating SOC therapy with radiotherapy and androgen deprivation remedy or with radical prostatectomy versus SOC plus docetaxel. The ultimate research cohort of two,184 sufferers included 145 eligible sufferers (6.6%) throughout 4 eligible RCTs.

“Of those 145 sufferers, 139 had glorious efficiency standing [PS] and have been the primary focus of the research. A superb PS identifies sufferers who can tolerate the total course of chemotherapy and due to this fact profit if the therapy proves efficient,” says Anthony Victor D’Amico, MD, Ph.D., chief of Genitourinary Radiation Oncology at Brigham and Girls’s Hospital and senior creator of the research.

Amongst these 139 sufferers, SOC plus docetaxel was related to a major 70% discount in PCSM and almost halved all-cause mortality. Remarkably, this therapy regiment dropped the 10-year PCSM price from almost 40% to lower than 10%, resulting in a 10-year general survival of 80% as in comparison with 60%.

“It is a marked enchancment in survival for these sufferers, who at present would not have any extremely efficient remedies,” Dr. D’Amico says.